GeneDx price target raised to $15 from $11 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on GeneDx to $15 from $11 and keeps a Buy rating on the shares ahead of its Q1 results next week. The firm has recently met with the company’s management team and came away “feeling good about the setup” on the stock at this level, the analyst tells investors in a research note. Despite the strong 250% run in the stock year-to-date, GeneDx shares trade at just 0.8-times of the Street’s 2025 revenue estimates, which is below small cap peers at 1.5-times, BTIG states, adding that the stock could run higher through 2024 and into 2025.